Literature DB >> 16633492

Concurrent substance-related disorders and mental illness: the North American experience.

Nady el-Guebaly1.   

Abstract

Ingredients of the evolving North American experience in addressing the management of patients with concurrent substance-related disorders and mental illness are presented. This experience as well as select data from Europe and Australia indicate a growing empirically-based consensus to provide an integrated approach to the care of these patients. It also highlights the necessity to conduct local surveys of needs and resources and adapt the published clinical experience to the local system of care, resources and culture.

Entities:  

Year:  2004        PMID: 16633492      PMCID: PMC1414708     

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  26 in total

1.  Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London.

Authors:  P J Duke; C Pantelis; M A McPhillips; T R Barnes
Journal:  Br J Psychiatry       Date:  2001-12       Impact factor: 9.319

2.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

Review 3.  Substance-related cravings and relapses: clinical implications.

Authors:  N el-Guebaly; D Hodgins
Journal:  Can J Psychiatry       Date:  1998-02       Impact factor: 4.356

4.  The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization.

Authors:  R C Kessler; C B Nelson; K A McGonagle; M J Edlund; R G Frank; P J Leaf
Journal:  Am J Orthopsychiatry       Date:  1996-01

5.  Prospective and retrospective reports of mood states before relapse to substance use.

Authors:  D C Hodgins; N el-Guebaly; S Armstrong
Journal:  J Consult Clin Psychol       Date:  1995-06

6.  Epidemiology of psychiatric disorders in Edmonton: phenomenology and comorbidity. Introduction.

Authors:  R C Bland
Journal:  Acta Psychiatr Scand Suppl       Date:  1994

7.  Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model.

Authors:  D M Ziedonis; K Trudeau
Journal:  Schizophr Bull       Date:  1997       Impact factor: 9.306

Review 8.  Substance abuse and mental disorders: the dual diagnoses concept.

Authors:  N el-Guebaly
Journal:  Can J Psychiatry       Date:  1990-04       Impact factor: 4.356

Review 9.  Review of integrated mental health and substance abuse treatment for patients with dual disorders.

Authors:  R E Drake; C Mercer-McFadden; K T Mueser; G J McHugo; G R Bond
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

10.  Drug and alcohol problems among individuals with severe mental illness in south London.

Authors:  P R Menezes; S Johnson; G Thornicroft; J Marshall; D Prosser; P Bebbington; E Kuipers
Journal:  Br J Psychiatry       Date:  1996-05       Impact factor: 9.319

View more
  3 in total

1.  Assertive community treatment and associations with substance abuse problems.

Authors:  Maaike D van Vugt; Hans Kroon; Philippe A E G Delespaul; Cornelis L Mulder
Journal:  Community Ment Health J       Date:  2013-06-15

2.  Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting.

Authors:  Linwei Wang; Dimitra Panagiotoglou; Jeong Eun Min; Kora DeBeck; M J Milloy; Thomas Kerr; Kanna Hayashi; Bohdan Nosyk
Journal:  Drug Alcohol Depend       Date:  2016-09-01       Impact factor: 4.492

3.  Changes in Loss Sensitivity During Treatment in Concurrent Disorders Inpatients: A Computational Model Approach to Assessing Risky Decision-Making.

Authors:  Stefanie Todesco; Thomas Chao; Laura Schmid; Karina A Thiessen; Christian G Schütz
Journal:  Front Psychiatry       Date:  2022-01-28       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.